Dual-layer spectral CT for predicting spread through air spaces in lung adenocarcinoma: a dual-center study
摘要
To investigate the value of machine learning classifiers incorporating dual-layer spectral CT (DLCT) parameters for preoperative prediction of spread through air spaces (STAS) in patients with lung adenocarcinoma.
Materials and methodsThis two-center retrospective study included 246 lung adenocarcinoma patients from center I (training cohort) and 193 patients from center II (test cohort). DLCT parameters and clinicoradiologic characteristics were collected. Univariable and multivariable logistic regression analyses were performed to identify independent factors for STAS, among which DLCT parameters were used to develop DLCT-based models (Model-DLCT) using five machine learning classifiers. Similarly, clinicoradiologic characteristics associated with STAS were subsequently combined with DLCT parameters to develop combined models (Model-COM). The prediction performances were evaluated using the receiver operating characteristic curve and decision curve analysis (DCA).
ResultsVenous phase electron density (odds ratio (OR) = 1.042, p = 0.02) and venous phase normalized iodine concentration (OR = 73.015, p < 0.01) were used to construct the Model-DLCT. Among the five classifiers, the extreme gradient boosting (XGBoost)-based Model-DLCT achieved the best performance, with AUC values of 0.833 [95% CI: 0.777–0.889] and 0.829 [95% CI: 0.773–0.886] in the training and test cohorts, respectively. The consolidation/tumor ratio (CTR, OR = 17.865, p = 0.01) was the only significant clinicoradiologic predictor. The combined model, integrating CTR with the Model-DLCT, demonstrated modestly improved discrimination with AUCs of 0.862 (95% CI: 0.812–0.911) and 0.832 (95% CI: 0.774–0.889) in the two cohorts. DCA further confirmed its clinical utility.
ConclusionA machine learning model integrating DLCT quantitative parameters with clinicoradiologic characteristics provides a robust tool for preoperative prediction of STAS in patients with lung adenocarcinoma.
Key Points